DarioHealth Corp. has entered into an amendment to its existing credit agreement with Callodine Commercial Finance, LLC and other lenders. The amendment resets certain financial covenants, waives financial-covenant testing for the second and third quarters of 2025, and replaces the minimum cash covenant with a $10 million minimum consolidated unencumbered liquid assets requirement. It also introduces a monthly 13-week cash-flow reporting obligation when liquidity falls below $11 million, subject to an EBITDA exception. Additionally, the amendment clarifies that an extra $2.5 million in funding is uncommitted and at the lenders' discretion, increases the exit fee by $150,000 (with a possible waiver under certain conditions), and reduces the exercise price of lender warrants and the conversion price on part of the loan. DarioHealth paid a $150,000 amendment fee in connection with these changes.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DarioHealth Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109166), on November 10, 2025, and is solely responsible for the information contained therein.
Comments